NFE2L2 and cancer: Mutations in PI(3)K/Akt, which are common in some cancer types, such as breast cancer, stabilize and activate NFE2L2, thereby promoting the upregulation of enzymes involved in synthesizing or reducing GSH (glutathione synthetase GSS, and glutathione reductase GSR; Lien et al., 2016).